On August 8, 2023, Celldex Therapeutics ($NASDAQ:CLDX) announced their earnings for the second quarter of FY2023, ending June 30, 2023. Revenue for the quarter came in at USD 0.3 million, representing a 68.8% year-on-year increase. Net income decreased from -36.0 million in the previous year to -30.5 million.
On Tuesday, August 8 2023, CELLDEX THERAPEUTICS reported their second quarter of the fiscal year 2023 earnings. The stock opened at $32.7 and closed at $32.4, down by 0.7% from prior closing price of 32.6. Investors have shown mixed reaction to the earnings report as the stock prices remained relatively stable after a slight dip of 0.7%.
The company expects to continue to grow in the coming quarter with positive cash flows and new product launches, as it expands its portfolio of innovative treatments and services for patients living with unmet medical needs. CELLDEX THERAPEUTICS is currently trading at $32.4 per share and investors are currently optimistic that the company’s recent earnings report will provide momentum for its stock to rise in the coming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Celldex Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Celldex Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Celldex Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Celldex Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Celldex Therapeutics Intrinsic Stock Value
GoodWhale has conducted an in-depth analysis on CELLDEX THERAPEUTICS’s financial wellness and according to our proprietary Valuation Line, the fair value of their shares is estimated to be around $37.7. However, the stock is currently being traded at $32.4 which is significantly lower than the fair value, undervalued at 14.0%. That presents a good opportunity for investors to buy shares in the company at a discounted price. More…
Risk Rating Analysis
Star Chart Analysis
The company’s products include CDX-014, CDX-1127, CDX-301 and CDX-3379. Celldex Therapeutics Inc has a strategic alliance with Bristol-Myers Squibb Company for the development and commercialization of CDX-014.
– Tyme Technologies Inc ($NASDAQ:ACET)
Adicet Bio Inc is a clinical-stage biopharmaceutical company that focuses on the development of cell therapies for cancer and autoimmune diseases. The company’s most advanced product candidate is a chimeric antigen receptor T cell therapy for the treatment of solid tumors. Adicet Bio Inc has a market cap of 651.7M as of 2022 and a Return on Equity of -9.85%. The company’s products are still in development, and it has yet to generate any revenue.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company that specializes in the development and commercialization of immunotherapy solutions for the treatment of cancer. The company has a market cap of 1.53B as of 2022 and a Return on Equity of -73.61%. Iovance Biotherapeutics Inc is headquartered in San Carlos, California.
Celldex Therapeutics reported strong second quarter financial results on August 8, 2023, with total revenue of $0.3 million, a 68.8% year-on-year increase. Net income over the quarter was -$30.5 million, a decrease from the previous year’s -$36.0 million. Investors should pay attention to the strong revenue growth, as well as the narrowing losses.
It is positive that revenue growth is outpacing the decline in net income, suggesting that the company’s investments are starting to yield results. Furthermore, investors should also consider the company’s prospects for future growth, as it looks to expand its product portfolio and capitalize on opportunities in the healthcare industry.